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Abstract:  14 
In Canada, 5.5 million (16% of Canadians) adults are >65 years old and projections suggest this 15 
number will be approximately 20% of Canadians by 2024. A major concern regarding old age is a 16 
decline in health, especially if this entails a loss of self-sufficiency and independence caused by a 17 
decline in cognition. The brain contains 60% of fat and is one of the most concentrated organs in long 18 
chain omega-3 fatty acids such as docosahexaenoic acid (DHA). During aging, there are physiological 19 
modifications in the metabolism of lipids that could also have consequences on brain structure and 20 
levels of DHA. This review will hence discuss the physiological modifications in the metabolism of 21 
lipids during aging with a focus on long chain omega-3 and omega-6 fatty acids and also outline the 22 
structural and functional modifications of the brain during aging including brain lipid modifications 23 
and its relation to higher levels of DHA and cognition. Therefore, in this review, we outline the 24 
importance of collecting more data on the biology of aging since it might highly improve our 25 
understanding about what are «normal» modifications occurring during aging and what can become 26 
pathological.  27 
 28 
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1. Introduction 33 
Almost every country in the world experiences an aging population, and this population is expected to be 34 
one of the most significant forces shaping our economy and society in the next 20-30 years. A major concern 35 
about old age, both at the individual and societal levels, is a decline in health, especially if this means a loss 36 
of self-sufficiency and independence. Increasing research aimed at promoting healthy aging is actually 37 
ongoing but one of the major hurdles is to define the biology of aging. Aging in humans refers to a 38 
multidimensional process of physical, psychological, and social changes. Therefore, it follows that 39 
fundamental knowledge on the biological processes occurring during aging may help to design 40 
environmental strategies aimed at promoting healthy biological aging. Thus, there is a need for better 41 
prevention strategies, but one major gap in this field is a need to better understand what the biological 42 
modifications are, also called geroscience, since this field is relatively new. One of the strategies to promote 43 
healthy aging is the consumption of one or two fish meals each week 1-3. Normally, the intake of fish 44 
positively correlates with increased plasma and erythrocyte omega-3 fatty acids (n-3 FA), likely with 45 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) concentrations in a time- and dose-46 
dependent manner 4-6. EPA and DHA have to be provided through the diet because their synthesis from their 47 
precursor alpha-linolenic acid (ALA) is extremely limited in humans 7. However, over the 20th century, the 48 
dietary fat consumption has drastically changed with an increased level of omega-6 fatty acids such as 49 
linoleic acid (LA) from 2.79% to 7.21% of energy. This shift in our dietary fat intake was largely due to our 50 
dependence on new food production methodologies, including soybean oil 8.  51 
The link between our dietary fat intake and the incidence of chronic diseases has been largely debated over 52 
the last 20 years. Our research group is mainly focused on prevention of cognitive decline, so the focus of 53 
this review paper, with respect to chronic diseases, will be on cognition. This link between dietary fat intake 54 
and the risk of cognitive decline has been the focus of many review papers overs the last 10-15 years 9-11. 55 
One of the most recent reviews supports a positive association between dietary and blood n-6: n-3 ratio and 56 
cognitive decline and incidence of dementia, as evaluated on 14 human studies including 7 prospective 57 
studies 12. A recent meta-analysis on 11 cohort studies evaluated the association between 299 metabolites 58 
and general cognitive ability and dementia. They reported that higher DHA levels in blood were associated 59 
with higher cognitive function in 22,887 individuals 13. Hence, it seems that more elevated concentration of 60 
n-3 FA in the blood is associated with lower cognitive decline and perhaps lower risk of other chronic 61 
diseases. However, our group showed that for older participants, plasma EPA and DHA kinetics are 62 
dysregulated and this will likely lower the capacity of older adults to incorporate EPA and DHA in organs 63 
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and tissues. Usually, a fish oil supplementation increases the level of EPA and DHA in the plasma or 64 
erythrocytes but in those aged >70 years old, we don’t know whether this process is efficient. There is no 65 
clear definition or parameters to define an old vs. a young participant. Most of the studies used the median 66 
of age in their participants group or a continuous age ae range. Following from the information summarized 67 
above, this paper will review some of the metabolism modifications occurring during aging with a focus on 68 
lipid metabolism. By reviewing these evidences, we will also expose how these modifications might limit 69 
incorporations of n-3 FA in membranes of cells with a focus on the brain because it is one of the most 70 
enriched organs in DHA.  71 
2. Lipid and fatty acid metabolism differences during aging  72 
Generally speaking, there are differences in the lipid and fatty acid metabolism occurring during aging 73 
and these modifications are considered totally normal and part of the aging process. These processes 74 
include the transport of fatty acids after their intake and their transit to the different organs and tissues 75 
that are modified during aging. This section will review some of these modifications.  76 
2.1.Normal transport of fatty acids from dietary intake to their circulation in the blood:  77 
In Western adults, the diet is composed of 30 to 40% of lipids, of which 92 to 96% are long chain 78 
fatty acid esterified to a glycerol thus constituting what is the main form of dietary lipid: triglycerides 79 
(TG) 14. Whole-body homeostasis requires fine-tuning of fatty acid transport and utilization by 80 
metabolically active tissues 15. Because of their regulatory roles in cellular fatty acid uptake and 81 
utilization, membrane apolipoprotein receptors and fatty acid transporters form an integral part of this 82 
homeostatic system. As a result, imbalances in lipid metabolism likely will influence the functioning 83 
of fatty acid transporters and their protein levels. Lipids are not soluble in water and necessitate 84 
incorporation into amphiphilic molecules called lipoproteins to circulate in the blood. Hence, 85 
following ingestion of TG, they will be hydrolysed at their ester bonds by gastric and pancreatic 86 
lipases into two non-esterified fatty acids (NEFA) and one monoacylglycerol (MAG) with the fatty 87 
acid being in the Sn-2 position 16. Both forms of lipids are passively transported into enterocytes 17 via 88 
diffusion or transporters such as "Fatty Acid Transport Proteins" (FATPs) and "Cluster of 89 
Differentiation 36" (CD36) 18. Dietary lipids are efficiently digested and absorbed by the enterocytes 90 
19.  91 
Once inside the intestinal cells, enzymes convert the NEFAs and MAG back into TG 20. These 92 
will be integrated in chylomicrons and exported to the lymphatic system via the Golgi apparatus 21. 93 
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The chylomicrons, now rich in exogenous triglycerides, join the bloodstream via the thoracic duct and 94 
get transported to the peripheral tissues such as muscle and fat cells. In the bloodstream, lipoprotein 95 
lipase (LPL) gets activated when it detects an apolipoprotein C II (apoC-II) 22 on the surface of the 96 
chylomicrons. The role of lipoprotein lipase is to hydrolyse the ester bonds of TGs in chylomicrons 22 97 
to release NEFAs into the bloodstream where there will be an uptake by nearby cells. The loss of TGs 98 
will result in a decrease in size of chylomicrons and leave chylomicrons constituents available for the 99 
synthesis of native HDL disks 23. Remnant chylomicrons rich in cholesteryl esters will be captured by 100 
endocytosis by hepatocytes receptors such as LDL receptor (LDLR) 22 and LDL receptor-related 101 
protein (LRP)  (https://onlinelibrary-wiley-102 
com.ezproxy.usherbrooke.ca/doi/abs/10.1002/%28SICI%291096-103 
9136%28199708%2914%3A3%2B%3CS75%3A%3AAID-DIA449%3E3.0.CO%3B2-9). The liver can then use 104 
the endogenous TG and cholesteryl esters to form the very low density lipoprotein (VLDL) 24. These 105 
lipoproteins will be directed to peripheral tissues. Following a loss of TG, there will be a decrease in 106 
VLDL density 25. With the action of lipoprotein lipase, VLDL will then become intermediate density 107 
lipoprotein (IDL). With the action of hepatic lipase 25 IDL becomes low density lipoprotein (LDL). 108 
LDLs carry cholesterol to tissues 26. LDL will be captured by their receptor, LDLR which are found 109 
on cell membranes, where it will be eliminated from the bloodstream by endocytosis 26. LDL 110 
cholesterol will be recovered in the cell. An excess of cholesterol in the tissues will cause an inhibition 111 
of transcription of the genes responsible for the formation of the LDLR 27. It thus reduces the uptake 112 
of LDL by the cells and these LDLs will remain in circulation. The remaining LDLs in the circulation 113 
are more likely to be oxidized 28 which will thereafter contribute to the development of atherosclerotic 114 
plaque 28. 115 
2.2 Lipoprotein metabolism modification during aging  116 
During aging, the metabolism of lipids is modified and causes an increase of plasma lipids. For instance, 117 
the fasting plasma levels of VLDL, TG, LDL and cholesterol 29 are significantly higher in the elderly 30. 118 
Higher levels of lipid and cholesterol can be the source of many health problems such as cardiovascular 119 
disease and diabetes (REF =http://diabetes.diabetesjournals.org/content/46/8/1354.full-text.pdf + 120 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587882/). 121 
These plasma lipid changes in the elderly can cause an increase in plasma free fatty acid levels (https://eds-122 
b-ebscohost-com.ezproxy.usherbrooke.ca/eds/pdfviewer/pdfviewer?vid=1&sid=3f462f39-8acd-4cbf-123 
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b113-b378e62a44c1%40sessionmgr103). Increasing plasma FFA may result in increased plasma glucose 124 
by decreasing glucose uptake into the cells. The enzymes responsible for the oxidative cascade of GLA are 125 
intimately related to that of glycolysis. Thus, increased lipid oxidation inhibits glucose metabolism, 126 
decreases glucose uptake in cells, and impairs glycogen storage 127 
http://diabetes.diabetesjournals.org/content/diabetes/37/6/667.full.pdf.. This promotes hyperinsulinemia 128 
and ultimate insulin resistance https://eds-b-ebscohost-129 
com.ezproxy.usherbrooke.ca/eds/pdfviewer/pdfviewer?vid=1&sid=3f462f39-8acd-4cbf-b113-130 
b378e62a44c1%40sessionmgr103. 131 
Insulin resistance, often seen in the elderly (https://www.jci.org/articles/view/110908/pdf), will also cause 132 
an increase in VLDL and blood triglycerides. Insulin resistance impairs the metabolism of chylomicrons, 133 
VLDL, LDL and HDL 31 since a lack of insulin or a lower sensitivity to insulin will reduce the catabolism 134 
of chylomicrons and VLDL by LPL. During aging, there is also a higher level of LDL which remains 135 
transient for a longer period of time in the plasma (Einarsson K, Nilsell K, Leijd B, Angelin B. Influence of 136 
age on secretion of cholesterol and synthesis of bile acids by the liver. N Engl J Med 1985;313(5):277-82. 137 
doi: 10.1056/NEJM198508013130501.) as a reference of this statement. = REF 30). In the long term, these 138 
LDLs are more likely to be oxidized 31. The higher concentration of VLDL and chylomicrons in addition to 139 
oxidized LDL accumulation in older insulin-resistant individuals would increase the risk of developing 140 
cardiovascular disease (CVD) 32. Furthermore, the increase of LDL may be due to the diminution of bile 141 
synthesis from cholesterol by the liver during aging 30, 33. The decrease in bile acid synthesis is due to the 142 
decrease in the expression of "cholesterol 7-alpha hydroxylase" (CYP7A1) during aging. This cytochrome 143 
is one of the CYP450 and regulates the formation of bile acids 34. This causes a decrease in the use of 144 
cholesterol by the liver as well as a reduction in LDLR expression with age. Thus, plasma LDL will have 145 
lower clearance with age resulting in an increase in plasma LDL concentration in the elderly 29. In the end, 146 
it is possible that deregulation of LDL in the elderly is due to several different phenomena stemming from 147 
the large amount of change that occurs with age. The decrease in LDL in the elderly has shown a reduction 148 
in the incidence of CVD 35. In particular, a study showed that long chain polyunsaturated fatty acids 149 
(PUFAs) allowed an increase in LDLR expression 36, which could increase the clearance rate of plasma 150 
LDL in the elderly and reduce the incidence of CVD. These are some of the modification of the lipid 151 
metabolism occurring during aging. Overall, there are usually higher TG and LDL levels in the blood of 152 
older adults and it is important to consider these modifications in the prevention of chronic diseases but also 153 
when interpreting results pertaining to fatty acid metabolism.  154 
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2.3 Omega-3 fatty acid metabolism during aging 157 
Over the last 10 years, our group has worked on omega-3 metabolism with a focus on modifications 158 
that occur during aging. This section will report the evidence of omega-3 fatty acid metabolism in 159 
three different conditions: before supplementation with omega-3, during or after supplementation with 160 
omega-3 fatty acid, and kinetics studies using uniformly labeled carbon 13 fatty acids (13C-).  161 
2.3.1 Without an omega-3 fatty acid supplementation  162 
To our knowledge, there are ~ 24 studies that have reported the level of omega-3 fatty acids or the 163 
omega-3 index in young versus old adults (Table 1). Most of the studies reported the fatty acid profile 164 
in red blood cells or in plasma/serum phospholipids (PL). Among the 24 studies, 7 studies reported 165 
the omega-3 index only and showed that it was higher in older participants 37-43. Two studies on the 166 
omega-3 index reported an increase of about 5-7% of the omega-3 index every decade 37, 41. Eleven 167 
studies reported the fatty acid profile in red blood cells (RBC) 37, 38, 41-50. For most of the studies, it is 168 
difficult to compare the results since the data were not expressed the same way. For instance, two 169 
studies reported that the participants having the highest level of omega-3 were on average 8-10 years 170 
older than those with the lowest omega-3 fatty acid levels in erythrocytes 43, 44. Other studies reported 171 
the level of increase in omega-3 fatty acids for each increasing decade. Hence, it is difficult to draw a 172 
clear conclusion for the omega-3 fatty acid results in RBC but it appears that at older ages, there is 173 
more omega-3 in RBC. It is important to note that these papers did not include a complete fatty acid 174 
profile of the RBC as it was recently recommended in a paper describing the best practices for the 175 
design, laboratory analysis and reporting of clinical trials involving fatty acids 51, hence limiting 176 
comparisons between studies. With respect to plasma/serum PL, there were eight studies 45, 52-58. Six 177 
of these studies reported on average a 1.5 fold higher level of DHA in the plasma PL of older 178 
participants, aged between 50-88 years old compared with younger participants, aged between 20-49 179 
years old 45, 53-57. One study reported a 2 fold higher level of EPA in plasma PL but there were no 180 
difference between ages for DHA 52. Yet another study reported only a positive correlation between 181 
age and EPA+DHA in plasma PL but it was not possible to quantify the magnitude of the difference 182 
between young and older adults 58. Overall, there is generally good evidence supporting the idea that 183 
during aging, the relative % of omega-3 fatty acids or its concentration in RBC and plasma/serum are 184 
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higher in the oldest participants compared to the youngest. Some of the proposed mechanism includes 185 
a reduction of omega-3 fatty acids in cell membranes, higher intestinal absorption during aging, higher 186 
availability and release of adipose tissue stocks. Hence, the exact mechanism behind this higher level 187 
of blood omega-3 in older individuals might be multi-level but the important point here is that they 188 
might be associated to longevity.  189 
2.3.2 With an omega-3 fatty acid supplementation 190 
To our knowledge, there are nine published studies specifically addressing EPA and DHA responses to an 191 
omega-3 fatty acid supplement with participants of different ages (Table 2). Supplementation doses range 192 
from 300 mg/d to more than 4 g/d and lasted between 6 weeks and twelve months. Seven studies evaluated 193 
the fatty acid profile in the plasma whereas one study evaluated the fatty acid profile in erythrocytes only 59 194 
and another did so in platelets and adipose tissues only 60. One study reported the omega-3 index pre- and 195 
post-supplementation 59 and showed that a low omega-3 index at baseline and an older age predicted those 196 
with a greater increase of the omega-3 index after supplementation 59. This study had similar results to 197 
Vandal et al., 61 which showed that the oldest had a higher increase in DHA compared to the youngest after 198 
the supplementation, but in their study, Vandal had similar DHA levels in young and old participants at 199 
baseline.  200 
The other studies investigated the plasma level of omega-3 fatty acids. One study reported that older 201 
participants had higher omega-3 levels at baseline but after the supplementation, the increase was similar in 202 
both groups 62. The six other studies reported a higher increase in EPA 63-67 and/or DHA 68 in older 203 
participants compared to younger. The exact mechanism explaining this effect is unclear. Most of the studies 204 
reported that it is unlikely that the age-related differences in EPA and DHA at baseline are due to differences 205 
in intake of omega-3 PUFA with age. Rather it seems to be related to age differences in endogenous 206 
production and incorporation of EPA and DHA due to hormones and hormone sensitivity, body 207 
composition, and physical activity, all of which change with age 67. The study of Walker et al. also showed 208 
that the adipose tissue stores less DHA with age in response to EPA + DHA supplementation, hence 209 
suggesting that age-related differences in the handling and storage of exogenous supplied DHA may be 210 
related to impaired insulin sensitivity with aging or to differences in body composition with aging 67. The 211 
adipose tissue represents a significant store of EPA and DHA, containing the equivalent of several hundred 212 
days of the fatty acid content of a typical diet. Altogether, these results support that providing a supplement 213 
of omega-3 fatty acid to older adults increases their blood levels when compared to younger individuals. 214 
These results may be caused by the fact that older individuals have shown to be more compliant to treatments 215 
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than younger people (REF = https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2710.2000.00315.x), 216 
causing a higher level of omega-3 in their blood. But despite that fact, those results brings into question 217 
whether this type of supplementation is useful to them in the prevention of chronic diseases since they may 218 
not be able to use it. Another important point is that it might also be due to their lower turnover of circulating 219 
TG, hence contributing to their higher omega-3 levels, since omega-3 fatty acid levels are esterified in TG. 220 
To answer some of these questions, employing 13C-fatty acids is useful.  221 
2.3.3 Using 13C-fatty acid to evaluate their kinetics during aging  222 
Tracing metabolism of 13C-fatty acids may provide some insight into possible age-related changes in 223 
fatty acid metabolism in humans. Metabolism of 13C-DHA has been investigated in humans 69-71. In 224 
young adults given an oral dose of 250-280 mg 13C-DHA, 13C enrichment peaked at 2 h post-dose in 225 
plasma triglycerides when the tracer was given in the triglyceride form, but at 6 h post-dose when the 226 
tracer was esterified to phosphatidylcholine 69, 71. Brossard et al. have reported a 1.4% apparent retro-227 
conversion of 13C-DHA to 13C-docosapentaenoate (22:5 omega-3) and 13C-EPA 3 d after giving the 228 
tracer 70. These first results showed the feasibility of tracing DHA metabolism in humans. However, 229 
neither the impact of aging on 13C-DHA metabolism nor its -oxidation were investigated, although 230 
both may influence the somewhat higher blood levels of EPA and DHA commonly seen in  healthy 231 
elderly 54, 65, 66, 68, 72. Our group are pioneers in this field as we investigated the kinetics of 13C-DHA 232 
in six young and six elderly participants 73. We found that, in the elderly, 13C-DHA was 4 times higher 233 
in plasma triglycerides and NEFA at 4 h post-dose, -oxidation was 1.9 times higher, whereas 234 
apparent retro-conversion of 13C-DHA to other 13C-omega-3 fatty acids was 2.1 times higher 24 h and 235 
7 d after tracer intake compared to the young adults 73. Hence, because DHA seems to remain 236 
transiently for longer periods of time in the blood of the elderly compared to the young, it may thus 237 
indicate that efficiency to remove DHA from the blood is lower in the elderly than in the young, 238 
resulting in lower incorporation of DHA in the membrane of cells that serve to initiate signalization 239 
65, 66, 68, 72. This result is consistent with the transient slower metabolism of TG and LDL in older as 240 
compared to young adults and this was described in a previous section.  241 
Our most recent work with tracers between old and young men was conducted with 13C-EPA or 242 
arachidonic acid (13C-ARA), two key fatty acids that are precursors of anti- and pro-inflammatory 243 
cytokines, respectively. Surprisingly, the kinetics of 13C-EPA and 13C-ARA was quite similar between 244 
young and old men despite a time x age interaction for 13C-EPA kinetics where the postprandial shape 245 
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of the curve was steeper in old vs young men 74. One intriguing result we obtained was that in old 246 
men, synthesis of DHA from EPA started 2 h after tracer intake whereas it was delayed to 1 d in young 247 
men. This result suggests that old adults might need more DHA than what was actually provided in 248 
their diet compared to the young men. However, newly synthesized DHA accumulated in the plasma 249 
of old men for 7 d and this might be because it remains for a longer period in the plasma as suggested 250 
by our previous study with 13C-DHA. Therefore, there might be a defect in old adults to uptake DHA 251 
in the tissues. We also calculated that plasma half-life of 13C-EPA was 2 d whereas that of 13C-ARA 252 
was 4 d, similar to that of DHA. DHA and ARA are the two most concentrated long chain 253 
polyunsaturated fatty acids in brain membranes. With our -oxidation measures using breath samples, 254 
we calculated 13C-EPA whole-body half-life to be ~14 days in old men whereas in the younger group 255 
it was ~21 days 74. This result indicates that older adults turn over EPA ~7 days faster than the younger 256 
adults. This is an intriguing result since epidemiological studies and results we obtained in previous 257 
studies 62, 65 support that old adults have twice as much plasma EPA, hence one would anticipate a 258 
lower whole-body turnover in old vs young adults. Therefore, it seems that there is somehow a 259 
disconnect between plasma levels of EPA and perhaps DHA and their kinetics, thus more studies are 260 
needed to understand the mechanism of these modifications and their possible consequences such as 261 
potential higher risk of cognitive decline.  262 
3 Brain modifications during aging: 263 
The brain is composed of 60% fat with one third of its content being ARA and DHA. The brain is 264 
hence the second most rich tissue in fat after adipose tissue. The brain fatty acids are however mostly 265 
PLs unlike the adipose tissue that is mainly composed of TGs. Because DHA is an important 266 
constituent of brain structure, there has been much interest in the association between the level of 267 
DHA in brain membranes, brain function and brain volume and losses during aging. Therefore, this 268 
section will summarize the evidence about morphological, functional, and content modifications of 269 
the brain during aging and whether dietary omega-3 intake can improve brain structure and function.  270 
3.1. Morphological modifications of the brain during aging 271 
There are a number of morphological modifications of the brain that occur during aging. Several 272 
studies have indicated that brain volume decreases over the course of the human lifespan. A review 273 
conducted by Hedman et al. 75 compiled the results of 56 longitudinal magnetic resonance imaging (MRI) 274 
studies on whole brain volumes in healthy individuals and concluded that the rate of total brain volume loss 275 
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is not constant throughout aging. For instance, the rate of brain volume loss after 35 years of age is 276 
approximately 0.2% per year. Between 35 and 60 years of age, the volume loss rate slowly increases to 277 
0.5% followed by a steady volume loss of over 0.5% per year over 60 years of age 75. Furthermore, other 278 
studies have indicated that volume loss in the whole brain is greater in males than in females 76, 77.  279 
Several studies demonstrate a reduction of gray matter volume during aging 78-84. More specifically, 280 
the volume of gray matter in the cortex and the cerebellum of older individuals is 18% and 13% smaller, 281 
respectively, than those of their younger counterparts 81. There is also a significant loss of gray matter in the 282 
frontal, limbic, temporal, and parietal lobes but not in the occipital lobe 78, 83. Similarly, studies have also 283 
indicated that there is a decrease of white matter volume in the brains of older individuals 81, 85-87. According 284 
to Jäncke et al. 81, there is a decrease in white matter volume in the cortex and cerebellum of older individuals 285 
by 5% and ~9%, respectively, compared to younger adults. Moreover, one study indicated that the rate of 286 
decrease of white matter is not constant during aging 87. Instead, white matter volume slowly increases 287 
before the age of 40, peaks at approximately 50 years of age, and then quickly decreases after the age of 60 288 
87. As well, white matter hyperintensity lesions increase in size with age in the frontal, temporal, and parietal 289 
lobes but not in the occipital lobes 86.  290 
In addition to age-related changes in the volume of the whole brain, gray matter, and white matter, there are 291 
also differences in the volume of specific brain structures. There seems to be a general decrease in the 292 
volume of the following brain structures in older individuals compared to younger individuals: cerebral 293 
hemisphere 76, frontal lobe 88, 89, parietal lobe 77, 88, 89, temporal lobe 88, 89, thalamus 81, 90, basal ganglia 89, 294 
and the cerebellum 89. Notably, there is atrophy of the hippocampus during aging 77, 81, 91-93. A meta-analysis 295 
by Fraser et al. 93 detailed hippocampal atrophy rates according to 28 studies. They determined that the 296 
overall rate of atrophy for the entire sample was 0.85% per year 93. However, the rate of hippocampal 297 
atrophy reported in the studies differed based on mean age of the participants: rate of atrophy was 0.38% 298 
per year in studies with a mean age of 55, 0.98% per year for a mean age of 55 to 70 years, and 1.12% per 299 
year for a mean age of greater than 70 years. In contrast to the aforementioned structures, the ventricles of 300 
the brain increase in volume during aging 76, 91. Altogether, there is generally good evidence supporting loss 301 
of matter in many brain structures, including loss in white and gray matter. These losses of brain matter can 302 
contribute to lower cognitive functions during aging.  303 
3.2  Modification of brain functions during aging 304 
Aging Research Reviews 12 
 
In addition to the many structural changes that occur during aging, brain functions are also modified during 305 
this period. For instance, there is an age-related decrease in glucose metabolism in the whole brain and the 306 
frontal, parietal, and temporal lobes as well as in Broca’s and Wernicke’s areas 77. It also seems that brain 307 
activation during the execution of motor functions is modified in older adults. For example, there is a 308 
decrease in blood-oxygen level dependent (BOLD) signals in multiple brain regions (sensorimotor cortex, 309 
cerebellum and thalamus) of older adults during mastication and an increase in BOLD signal in the 310 
prefrontal area 94. Another study showed that classical motor coordination regions were activated during 311 
complex inter-limb coordination tasks, but that there was also increased activation of higher-level 312 
sensorimotor and frontal regions in older individuals 95. Similarly, other studies have demonstrated that the 313 
performance of motor tasks result in increased activation of additional brain areas such as the basal ganglia, 314 
prefrontal cortex, precuneus, and the cerebellum 96-98 in older invividuals.  315 
Moreover, cognitive functions are modified as a result of changes in the volume of various brain structures. 316 
For instance, a meta-analysis of 57 publications from the years 1984 to 1998 concluded that white matter 317 
hyperintensities are linked with poorer performance on cognitive tests for processing speed, immediate and 318 
delayed memory, executive functions, and global cognitive functioning 99. Further, a decrease in the 319 
thalamus volume in older individuals is associated with attenuated performance on tests assessing cognitive 320 
speed 90. An additional meta-analysis of 33 studies concluded that larger prefrontal cortex volume and 321 
thickness is correlated with better executive functioning 100. In regard to hippocampus volume and memory, 322 
Van Petten 101 reported in a meta-analysis of 33 studies that the positive correlation between hippocampus 323 
size and episodic memory in older adults was weaker than expected. However, a more recent study 324 
demonstrated that smaller hippocampus size is significantly associated with lower performance in episodic 325 
memory, working memory, processing speed, and executive function tasks 102. Similarly to motor function, 326 
it has been shown that older adults recruit additional brain regions during memory tasks 103-105. 327 
Aging is also associated with changes in the activity of brain structures involved in sensation and perception. 328 
For instance, there are less areas activated in older versus younger adults in response to various odors 106. A 329 
meta-analysis of 105 studies concluded that the activation of the fusiform gyrus, cerebellum, and 330 
hippocampus is elevated in elderly versus younger individuals during the processing of emotional faces 107. 331 
Moreover, older individuals had greater activation of the prefrontal cortex during more difficult perceptual 332 
tasks compared to younger individuals 108. The brains of older adults are also less responsive to blue light 333 
stimulation compared to younger adults 109.  334 
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More recent studies have shed light on the changes that occur in the functional neural networks of the brain. 335 
It seems that aging is associated with weaker connectivity in long-range connections and stronger 336 
connectivity of short-range connections 110, 111. Elderly individuals also have less intra-network and greater 337 
inter-network connectivity 112, 113. More specifically, older individuals have less connectivity within the 338 
default mode network (DMN) and somatomotor network 113, as well as greater connectivity between the 339 
salience network and the executive control network (ECN) and the DMN 112. Moreover, age seems to shift 340 
dynamic functional connectivity from posterior to anterior regions, which is also reflected in the decreased 341 
activation of posterior regions during the decline of episodic memory in older individuals 114. 342 
Overall, there are several morphological and functional modifications within the brain during aging and 343 
understanding how these modifications manifest could be helpful to limit the rate at which these declines 344 
occur.  345 
3.3 Modifications of brain content during aging 346 
The number of studies, particularly those that use neuroimaging techniques, that have evaluated the change 347 
in human brain content during aging is limited. Post-mortem examinations of the human brain have 348 
indicated that there is a change in protein and lipid content during aging. With regard to protein, one study 349 
indicated that there is a 5-15% decrease in total protein content of the brain between 30 and 90 years of age 350 
115. A decrease in protein content in the substantia nigra, hippocampus, caudate nucleus, and gray matter 351 
has also been reported 116, 117. However, Söderberg et al. 116 found that protein content remained unchanged 352 
in the cerebellum, pons, and medulla oblongata of older individuals. Similarly, a number of post-mortem 353 
studies have demonstrated changes in the lipid content of older brains. For instance, Svenerholm et al. 118 354 
reported that there is a linear decrease in cholesterol and phospholipids in the frontal and temporal cortices 355 
and a curvilinear decrease in cholesterol, PLs, cerebrosides, and sulfatides in frontal and temporal white 356 
matter between the ages of 20 and 100. In terms of PLs, Söderberg et al. 116 found that they were relatively 357 
unchanged during aging with only a 5-10% decrease in the oldest age group. A more recent study conducted 358 
by Hancock et al. 119 reported that PL content in the entorhinal cortex of older individuals is relatively stable 359 
during aging, but there is an increase in mitochondrial phosphatidylcholine (PC) and a decrease in 360 
mitochondrial phosphatidylethanolamine (PE). The same group reported that age is associated with an 361 
increase in mitochondrial PE containing DHA, but said the increase is not large enough to increase total 362 
DHA in the mitochondria. Norris et al. 120 examined phospholipid composition in the dorsolateral prefrontal 363 
cortex in individuals aged 20-100 years. They found that there is a general age-related increase in 364 
phospholipids containing DHA and decrease in PLs containing ARA and docosatetraenoic acid 120.  365 
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A recent study used positron emission tomography to assess the incorporation of DHA from plasma to the 366 
brain using carbon-11 ([1-C11])-DHA in apolipoprotein E epsilon 4 allele (APOE4) carriers versus non-367 
carriers 121. APOE4 is the most important genetic risk of late-onset Alzheimer’s disease 122. Yassine et al. 368 
found that the mean global gray matter DHA incorporation coefficient was 16% higher in APOE4 carriers 369 
vs non-carriers 121. A higher DHA incorporation coefficient was also observed in other regions including 370 
the entorhinal cortex 121. However, the whole-brain DHA incorporation rate was not significantly different 371 
between APOE groups 121. They also did not observe any age-related effects on DHA incorporation, but this 372 
may be due to the fact that only 4 of their 23 participants were over 50 years old 121. The authors 373 
hypothesized that increased DHA incorporation in the brains of APOE4 carriers could be a compensatory 374 
mechanism to counteract brain DHA loss 121. Our group also documented that the metabolism of DHA is 375 
imbalanced in APOE4 carriers 123-126 and that they are perhaps more vulnerable to DHA deficiency 127. 376 
3.4 Does omega-3 fatty acid consumption improve brain structure and function? 377 
There are a number of studies that have examined the relationship between omega-3 fatty acid consumption 378 
and brain structure and function. For instance, Gu et al. 128 evaluated the link between white matter integrity 379 
and dietary nutrient intake in 239 elderly participants. They assessed white matter integrity using fractional 380 
anisotropy measured by diffusion tensor imaging (DTI). They found that the nutrient pattern characterized 381 
by high consumption of omega-3 and omega-6 fatty acids and vitamin E was positively correlated with 382 
fractional anisotropy which corresponds to better white matter integrity 128. Another group examined the 383 
relationship between dietary fish consumption and brain structural integrity in 260 cognitively normal adults 384 
aged 65 years or older 129. Fish intake was measured using the National Cancer Institute Food Frequency 385 
Questionnaire and the gray matter volume of various brain regions was measured with MRI 129. They found 386 
that eating baked or broiled fish weekly is positively associated with higher gray matter volume in several 387 
brain regions, including the hippocampus, posterior cingulate, precuneus, and the orbital frontal cortex 129. 388 
Samieri and colleagues 130 evaluated the association between plasma EPA and DHA concentrations and 389 
gray matter atrophy in the medial temporal lobe in 281 individuals aged 65 years or older. The authors 390 
compared fatty acid plasma concentrations at baseline to the results of MRI examinations from baseline and 391 
four years after baseline 130. They observed that greater levels of plasma EPA was associated with lower 392 
atrophy of the gray matter of the right amygdala and the hippocampal/parahippocampal region; this same 393 
association was not observed for plasma DHA levels 130, which is counterintuitive. Samieri et al. 130 also 394 
found that increased amygdala gray matter atrophy was linked with more depressive symptoms and poorer 395 
semantic memory performances compared to baseline. Lastly, Witte et al. 131 assessed the connection 396 
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between fish oil supplement consumption and brain structure and function in 65 participants aged 50 to 75 397 
years. Participants consumed either fish oil, which contained 2.2 grams of omega-3 fatty acids, or a placebo 398 
daily for 26 weeks. Neuropsychological testing and MRI examinations were performed before and after the 399 
intervention period. The investigators found that after the 26-week intervention period, the fish oil group 400 
had better white matter structural integrity in selective white matter tracts in the frontal, temporal, parietal, 401 
and limbic areas 131. They also observed that the fish oil group had significant increases in gray matter 402 
volume in the left hippocampus, precuneus, the superior temporal, inferior parietal and postcentral gyri, and 403 
in the right middle temporal gyrus 131. In terms of performance on cognitive measures, they found that the 404 
fish oil group had an improvement of 26% on executive function scores compared to no improvement in the 405 
placebo group 131. In addition, they found a positive correlation between verbal fluency scores and EPA 406 
percentage in red blood cell membranes in the fish oil group after intervention 131. Although for many years 407 
it was thought that an intake of fish throughout life protects against cognitive decline, the recent evidence 408 
suggests that fish intake might not be required throughout life to improve brain structure and function. 409 
Hence, starting an EPA+DHA supplementation after 50 years old might benefit older individuals with 410 
respect to prevention of brain volume and function losses.  411 
4 Are we ready for updated recommendations on dietary omega-3 fatty acids intake during aging? 412 
In this review paper, we have outlined that there are many physiological modifications occurring during 413 
aging with respect to lipid metabolism and brain volume and function losses and that an omega-3 fatty 414 
acid intake might help to support the brain throughout aging. It is important to note that life expectancy 415 
is longer, which means that older adults may live longer with their chronic diseases. A major concern 416 
regarding old age is a decline in health, especially if this entails a loss of self-sufficiency and 417 
independence caused by a decline in cognition. A decline in working memory appears to be one of the 418 
major consequences of normal aging 132, 133. As outlined in the previous sections, the brain undergoes 419 
physiological change during aging. While age is one risk of cognitive decline, this multifactorial disease 420 
is also increased by a complex interaction between both genetic and environmental risk factors 134-136.  421 
We believe nutrition has a role to play in the prevention of cognitive decline but nutrition alone might 422 
not be as efficient as a multidomain intervention. Recent evidence from the FINGER trials 137 reported 423 
that combining physical exercise, personalized nutritional recommendations to avoid nutrient 424 
deficiencies, controlling cardiovascular risks and having cognitive stimulation prevented cognitive 425 
decline. However, they recently refocus their message by showing that dietary changes initiated early in 426 
the intervention was the most influential for global cognition improvement over two years of follow-up 427 
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138. Therefore, nutrition might have a key role to play in the prevention of cognitive decline. In the case 428 
of the FINGER study, dietary recommendations were not focussed on the consumption of fish oil but 429 
were either focused to alleviate nutritional deficiency including low blood levels of DHA. It also has to 430 
be emphasized that there is currently no drug to prevent, cure or delay the progression of dementia and 431 
that some pharmaceutical companies have shut down their research laboratories in this area. Therefore, 432 
prevention strategies are currently the most efficient means since once the disease process has started, 433 
there is no available drug for limiting its progression. However, there is one group in Canada working 434 
on a nutritional strategy, a ketogenic beverage. They reported that a ketogenic beverage increases brain 435 
energy metabolism in Alzheimer’s patients 139, 140.  436 
Returning to the question of if we are ready to change recommendations on omega-3 fatty acids, we think 437 
that we are not there yet. However, working on the biology of aging might greatly improve our 438 
understanding about what are «normal» modifications occurring during aging and what can become 439 
pathological. Seizing this opportunity, we might contribute to the prevention of cognitive decline in the 440 
future with nutrition playing a vital role in this process.  441 
  442 
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 794 
Table 1: Cross-sectional modulation by age of blood fatty acid  795 
    
Age-increasing effects at baseline in blood pool 
Reference n, sex and age Blood pool Age-increasing effects Omega-3 index EPA DHA 
43 n=460, 299 men and 161 
women, 29-97 y (~72 y) 
RBC                                                  
9.8 y older in Higher Omega-3 
Index Quartile compared to 
Lower Quartile 
Higher Omega-
3 Index quartile 
were 9.8 y 
older vs lower 
quartile 
  
52 53 institutionalized 
elderly subjects (24 men 
and 29 women), ≥ 60 y (~ 
79 y); 24 young healthy 
adults, 20 – 42 y (~29 y) 
Plasma NEFA, TG, CE 
and PL                           
In plasma PL: EPA higher in 
elderly; DHA and DPA: appear 
lower in the elderly but non-
significantly different 
  
PL: 2.1 fold 
higher 
  
44 768 acute coronary 
syndrome patients and 
768 matched controls (66 
% male, ~61 y) 
RBC membranes                        Positive relation between age 
and EPA and DHA levels: 8 years 
older in those with higher EPA + 
DHA levels vs those with lower 
group 
 
Higher RBC EPA 
+ DHA  group: 8 
y older 
compared to 
Lower group 
Higher RBC EPA 
+ DHA  group: 8 
y older 
compared to 
Lower group 
37 704 outpatients (67% 
male), ~62 y 
RBC RBC Omega-3 Index increases 
with age  
5.3% increase 
by 10 years 
increase 
    
45 15 centenarians (12 
females and 3 males),~ 
103 y (101–107 y), living 
in a family unit, self-
sufficient and without 
major illnesses and 13 
normal subjects (6 males 
and 7 females), ~65 y (6.0 
– 69 y) 
RBC-PL Increased DHA in RBC-PC and in 
RBC-PE, and increased DPA in 
RBC-PS and RBC-PE; 
  
PC: 2.2 fold 
higher               PE: 
1.6 fold higher 
53 2793 New Zealanders ≥15 
y (men and women) 
Serum PL, CE and TG Serum PL: EPA and DHA 
increase with age in both sexes 
while DPA increases with age 
only in women aged between of 
20 and 73 y 
  
PL: in both 
sexes, 
increased by 
0.3 mol% 
between 20 
and 73 y 
PL: in both 
sexes, increased 
by 0.3 mol% 
between 20 and 
73 y 
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54 234 men and women 
(Dutch: low fish 
consumption), 36 to 88 
years (~60 y) 
Plasma PL                                         Significant positive relationship 
between age and plasma PL 
concentrations of DHA and EPA.  
 
PL: ~1.5 fold 
increased 
between 36 to 
88 y 
PL: ~1.3 fold 
increased 
between 36 to 
88 y 
56 426 Inuits, 18 to 74 years: 
179 men (~38.7 y) and 
247 women (~37.8 y), 
n=254 in 18-39 y and 
n=172 in ≥40 y 
Plasma PL                                        Concentrations of EPA, DHA 
and EPA + DHA increased 
significantly with age   
2.4 fold higher 
in ≥40 y group 
compared to 
18-39 y group 
1.4 fold higher in  
≥40 y group 
compared to 18-
39 y group 
57 1460 subjects, 18–74 
years: 722 men (~40.6 y) 
and 738 women (~39.6 y), 
n=784 in 18-34 y, n=432 in 
35-49 y and n=244 in 50-
74 y 
Plasma PL                                        Older persons had higher EPA, 
DHA, EPA+DHA, EPA: AA and n-
3: n-6 ratio in older vs younger 
individuals 
 
1.1 fold higher 
in 50-74 y 
compared to 
18-34 y 
1.2 fold higher in 
50-74 y 
compared to 18-
34 y 
55 917 subjects, 18-74 y: 422 
men (~36.0 y) and 495 
women (~35.6 y), n=536 
in 18-34 y, n=220 in 35-49 
y and n=161 in 50-74 y 
Plasma PL                                                 EPA: AA, n-3: n-6 FA, and 
concentrations of EPA, DHA, 
and EPA+DHA did not vary 
according to sex, but there was 
a significant increase in the 
concentrations with age 
  
2.5 fold higher 
in 50-74 y 
compared to 
18-34 y 
1.7 fold higher in 
50-74 y 
compared to 18-
34 y 
47 992 participants (mainly 
men: >80%), age: early 
50s to late 70s 
RBC membranes                   Lower levels EPA + DHA were 
significantly associated with 
younger age 
 
  
38 446 women, ~48,5 y 
(40−60 y) 
RBC membrane                   In women aged ≥50 years, EPA 
and DPA levels and omega-3 
index were significantly higher 
compared to women under the 
age of 50 years.  
4% higher in 
≥50 y 
compared to 
<50 y 
13% higher in 
≥50 y 
compared to 
<50 y 
  
40 n= 3196, 55 % women, 
~66 y (40-74 y) 
RBC                                                      RBC Omega-3 Index increases 
with age 
5% increase 
every decade  
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41 159 771 patients (48% 
males, 52% females) 
being evaluated by their 
physicians for CVD risk  
RBC                Increases in EPA and DHA each 
decade. After age 70, significant 
decrease in EPA while DHA 
remain high 
7% increase by 
decade until 70 
y, stable 
thereafter 
13% increase 
by decade up to 
70 y, then 9% 
decrease by 
decade  
6% increase by 
decade until 70 
y, stable 
thereafter 
39 6501 women aged 65–80, 
~15 years follow-up 
RBC                        RBC Omega-3 Index increases 
with age:  
Higher Omega-
3 index 
quartile:  0.6 y 
older 
compared to 
lower quartile  
  
48 n=456, 320 men and 136 
women, 18 to 70 y (~42.5 
y) 
RBC-PL     EPA+DHA: ~1.4 fold increase in 
both gender between 18-20 vs  
60+ years       
141 411 Japaneses (194 men 
and 217 women), 418 
Koreans (240 men and 
178 women) and 252 
Mongolians (100 men and 
152 women) aged 30-60 y 
Plasma               EPA and DHA increase with age 
in Japanese and Koreans.   
 
Japaneses: 1.4 
fold increase  
Koreans: 1.9 
fold increase 
Japaneses: 1.2 
fold increase 
Koreans: 1.3 fold 
increase     
Mongolians: 1.1 
fold decrease 
58 75 adults admitted for 
elective surgery: 48 men 
(~58 y: 27-81 y) and 27 
women (~58 y: 33-74 y) 
Plasma PL, RBC-PL and 
AT                          
Positive correlation between 
EPA+DHA and age, in plasma 
and RBC-PL but not in AT       
42 163 adults, 74 men and 89 
women, 20 to 80 years 
RBC                                                    Omega-3 Index increased each 
decade but decreased by 0.3 
units with each 3-unit increase 
in BMI 
0.5 unit 
increase by 10 
years of age 
  
142 119 subjects for each 
population, Icelandic (59 
males and 60 females) 
and Icelandic-Canadians 
Plasma PL Young Icelandic-Canadians had 
lower levels of EPA than the 
middle and oldest age groups   
1.8 fold 
increase in 
oldest group 
compared to 
the youngest  
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(60 males and 59 
females), 20-69 years 
143 54 women, 43-60 years: 
19 premenopausal (~48 
y), 16 postmenopausal 
not receiving HRT (~52 y) 
and 19 postmenopausal 
receiving HRT (~51 y) 
Serum PL                                                      DHA levels were significantly 
lower in premenopausal 
women than postmenopausal 
women. Those receiving HRT 
had significantly lower levels of 
DPA. 
  
1.3 fold increase 
in 
postmenopausal 
women without 
HRT vs 
premenopausal 
144 338 women; alcohol 
intake: abstainers (n=254, 
~24,2 y), occasional 
(n=45, ~27,9 y) and 
habitual (n=8, ~30,5 y) 
Plasma and RBC  DHA and AA correlates 
positively with maternal age 
    
↑ in plasma 
(µg/ml et %)           
↑ in RBC (%) 
49 99 Icelandic women, 18 to 
73 y (~45.8 y) 
RBC      Proportions of total n-3 PUFA, 
EPA, and DHA correlated 
positively with age 
 ↑ ↑ 
145 200 Japaneses, 126 males 
and 74 females, ~50 y 
(<35 to ≥65 y) 
Serum and RBC total 
lipids                 
EPA, DHA, n-3: n-6 ratio and 
EPA: AA ratio increased with 
age (stronger effect in serum):  
  
Group ≥65 y 
compared to 
group <35 y: 2.3 
fold increase in 
serum and 2 
fold increase in 
RBC 
Group ≥65 y 
compared to 
group <35 y: 1.7 
fold increase in 
serum and 1,2 
fold increase in 
RBC 
AA: arachidonic acid, EPA: eicosapentaenoic acid: DHA, docosahexaenoic acid: DPA: docosapentaenoic acid, AT: adipose tissue, PUFA: 796 
polyunsaturated fatty acids, FA, fatty acids, PC: phosphatidylcholine, PE: phosphatidylethanolamine, PS: phosphatidylserine, CE: cholesteryl 797 
esters, NEFA: non-esterified fatty acids, RBC: red blood cells, HRT: Hormone receiving therapy, BMI: body mass index,     798 
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Table 2: Blood fatty acid modulation by age after an omega-3 fatty acid supplementation 799 
Reference n, sex and age Blood pool  Omega-3 
supplementation 
Age effects 
59 n=115, 60 men and 55 
women, 20 to 45 years 
RBC 5 doses (0, 300, 600, 900, 
1800 mg) of EPA+DHA 
(fish oil) for ~5 months 
Lower Omega-3 Index (O3I) status (P<0.0001) and 
older age (P=0.02) each predicted greater increases in 
O3I with supplementation 
62 24–28 participants in each 
age group (except as noted 
in the tables), young adult 
= 18-34 y (~23 y) and 
elderly group = ≥65 y (~74 
y) 
Plasma                                                          Two supplementations: n-
3 supplement enriched in 
DHA (680 mg DHA/d plus 
323 mg EPA/d) for 3 
weeks, or a supplement 
enriched in EPA (1480 mg 
EPA/d plus 250 mg 
DHA/d) for 6 weeks 
Expressed as % of total fatty acids: At baseline, total n-
3 PUFA, EPA and DPA higher in elderly (32%, 100% and 
25% respectively); Expressed as concentration (mg/L): 
At baseline, total n-3 PUFA, 18:3n-3, DHA, DPA and 
EPA higher in elderly (74%, 40%, 63%, 85% and 142% 
respectively); After supplementation: no higher effect 
with increasing age 
63 15 young (22-35 y) and 10 
older (51-71 y) women 
Plasma                                                                    Daily 1680 mg EPA and 
720 mg DHA for 3 months 
Older women had a significantly higher increase in EPA 
and DHA than did young women (EPA: 10-fold vs 8-fold 
and DHA: 2.5-fold vs 2-fold) 
64 6 young (23-33 y) and 6 
older (51-68 y) women 
Plasma                                         Daily 1680 mg EPA and 
720 mg DHA for 3 months 
At baseline there was no difference in percentage of 
EPA and DHA between young and older women; 
however, after 3 mo of (n-3) fatty acid 
supplementation, older women had a significantly 
higher percentage of EPA and DHA: EPA: 10-fold vs 5-
fold and DHA: 2.5-fold vs 1.6-fold 
65 10 young (5 men and 5 
women, ~22 y) and 10 
elderly (5 men and 5 
women, ~ 75 y) 
Plasma                    EPA-enriched supplement 
(1.4 g/d of EPA and 0.2 g/d 
of DHA) for 6 wk 
Before and after the EPA supplement, fasting plasma 
EPA was higher in the elderly (by 85% and 67% 
respectively) 
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66 Young (18-42 y; n=93) and 
old (53-70 y; n=62) men 
Plasma and MNC PL           Placebo (corn oil) or 1.35, 
2.7, or 4.05 g EPA/day for 
12 wks 
In both plasma and MNC PL : at baseline, EPA and DPA 
increase with age while after supplementation, only 
EPA increases in old men; at baseline, EPA, DPA and 
DHA respectively ~1.3, ~1.1 and ~1.4 higher in older in 
plasma and EPA and DHA respectively ~1.3 and ~1.25 
higher in older in MNC; with High-EPA 
supplementation: EPA and DPA respectively ~1.6 and 
~1.3 higher in plasma and EPA ~1.4 higher in MNC 
61 Elderly (n=9, 5 males and 4 
females, 74 y) and young 
(n=10, 5 males and 5 
females, 24 y) 
Plasma 680 mg/day of DHA and 
320 mg/day of EPA for 3 
weeks, followed by 2 
weeks of wash-out  
Higher baseline plasma EPA in elderly group; In 
response to the supplement, plasma DHA rose 42% 
more in the elderly but EPA responded similarly in 
both groups 
67 n=193 (101 women, 92 
men), 20–79 y 
Plasma PC, CE, NEFA 
and TG; MNC; RBC; 
PLAT; BU; AT 
EPA+DHA equivalent to 0, 
1, 2 or 4 portions of oily 
fish per week, for 12 
months 
At baseline, EPA in AT and DHA in plasma TG and AT 
higher with increasing age; Following 
supplementation, EPA in plasma TAG higher with 
increasing age while DHA in AT smaller with increasing 
age 
60 92 Danish women: half 
premenopaused (~43 y) 
and half postmenopaused 
(~56 y), 18-70 y 
PLAT, AT      2,2 g of marine n-3 PUFA 
(38,5% 
EPA, 25,9% DHA and 6,0% 
DPA) or control oil (thistle 
oil) daily for 12 weeks 
Baseline contents of EPA, DPA and DHA were all 
significantly lower (P<0.05) in premenopausal group 
both in platelets and adipose tissue, except for EPA in 
platelets (P=0.05); After supplementation, increase in 
platelets and adipose tissue was, however, the same 
in both groups 
EPA: eicosapenaenoic acid, DHA, docosahexaenoic acid, DPA: docosapentaenoic acid, PLAT: platelets, AT: adipose tissue, PUFA: 800 
polyunsaturated fatty acids, PC: phosphatidylcholine, CE: cholesteryl esters, NEFA: non-esterified fatty acids, MNC: mononuclear cells, RBC: 801 
red blood cells, BU, buccal cells,   802 
